Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 2/20 | 0.49 |
| ▸ | F7 | P08709 | 3/20 | 0.41 |
| ▸ | F3 | P13726 | 3/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.36 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.34 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.34 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 2/20 | 0.34 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.34 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.33 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.33 |
| ▸ | ALKBH3 | Q96Q83 | 1/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13850721 | 0.96 | PTGES (0.48) | PTGESF7F3SCN9AP4HTM | |
| SCHEMBL13850969 | 0.95 | PTGES (0.47) | PTGESF7F3SCN9AP4HTM | |
| SCHEMBL979520 | 0.84 | PTGES (0.46) | PTGESF7F3SCN9AP4HTM | |
| SCHEMBL978314 | 0.83 | PTGES (0.61) | PTGESF7F3SCN9AP4HTM | |
| SCHEMBL976706 | 0.81 | PTGES (0.57) | PTGESF7F3P4HTMPTGES2 | |
| SCHEMBL977413 | 0.81 | PTGES (0.56) | PTGESF7F3PTGES2 | |
| SCHEMBL13846292 | 0.79 | PTGES (0.56) | PTGESSCN9AKAT6A | |
| SCHEMBL979290 | 0.77 | PTGES (0.53) | PTGESF7F3PTGES2KAT6A | |
| SCHEMBL979144 | 0.76 | PTGES (0.81) | PTGESF7F3PTGES2KAT6A | |
| SCHEMBL979494 | 0.74 | PTGES (0.55) | PTGESSCN9AP4HTMPTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131468-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 065 | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131468-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 065 | PTGER1, CYP3A5, SULT1E1 | PTGES 9/4885F7 3496/4885F3 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.